Kentucky Researchers Identify Systemic Gaps Preventing Hormone Therapy Use in Cervical Cancer Survivors

UK Markey Cancer Center study identifies capacity and guideline gaps preventing cervical cancer survivors from accessing necessary hormone therapy.

By: AXL Media

Published: Apr 18, 2026, 4:47 AM EDT

Source: Information for this report was sourced from University of Kentucky Markey Cancer Center

The Hidden Cost of Life-Saving Pelvic Radiation

For premenopausal patients diagnosed with cervical cancer, the standard treatment of chemoradiotherapy—a simultaneous delivery of chemotherapy and radiation—often results in a high physiological price. Pelvic radiation frequently causes irreversible ovarian ablation, plunging women into iatrogenic menopause within weeks of treatment. This sudden transition brings a host of debilitating symptoms, including severe hot flashes, sleep disturbances, and vaginal dryness, yet many patients are left to manage these symptoms without medical intervention. A study led by University of Kentucky Markey Cancer Center radiation oncologist Denise Fabian, M.D., highlights that while the oncology community is willing to assist, systemic friction often prevents the transition from intent to prescription.

Survey Reveals Disparities Between Provider Specialized Groups

The research team conducted a national survey involving 178 clinicians from the Society for Gynecologic Oncology and the American Brachytherapy Society. The results showed a significant consensus on the utility of hormone therapy (HT), with 99.3 percent of gynecologic oncologists and 73.8 percent of radiation oncologists stating they would consider prescribing the treatment. Despite this nearly universal support among specialists, the research revealed a "knowledge-to-practice" gap. Gynecologic oncologists were found to be significantly more comfortable with the initial prescription, while radiation oncologists often felt less equipped to manage the hormonal aspects of survivorship care.

Capacity Constraints and Guideline Awareness Gaps

The study identified two dominant barriers that hinder the delivery of optimal survivorship care. First, many clinicians cited an inadequate capacity to provide the longitudinal, long-term management required for menopausal health. Systemic limitations, such as time constraints and a lack of integrated survivorship care models, make it difficult for oncologists to monitor hormone levels and symptom management over several years. Second, a notable lack of awareness regarding existing clinical guidelines was reported. Many providers were simply unfamiliar with the formal protocols that establish HT as a safe and effective option for cervical cancer survivors, leading to a pervasive but unfounded reluctance to prescribe it.